Peptide reconstitution

What does reconstitution involve for an approved peptide?

Egrifta WR's FDA label spells out the process for that one product: "Use only the diluent provided, Bacteriostatic Water for Injection, USP, to reconstitute EGRIFTA WR," discard the mixed solution "7 days after mixing," do not freeze or refrigerate it once mixed, and "record the date of first use" of the diluent bottle, which must be discarded 28 days after first use [1]. These rules are specific to that one approved product; each label sets its own rules, and this page describes none for any other peptide.

What is in the diluent, and why does it matter?

Bacteriostatic Water for Injection is a sterile solution containing 0.9% or 1.1% benzyl alcohol as a preservative, labeled "FOR DRUG DILUENT USE ONLY" [2]. Its label warns that benzyl alcohol "must not be used" in this way for neonates because of toxicity concerns, and that some injectable drugs "may be incompatible" when combined in the same vehicle [2]. For unapproved peptides, FDA repeatedly cites "risk for immunogenicity for certain routes of administration due to the potential for aggregation or peptide-related impurities," a concern about the peptide product itself rather than the diluent [3].

Why does peptide quality affect reconstitution safety?

Freeze-drying stresses a peptide before it is ever reconstituted, and manufacturers set a moisture specification for each freeze-dried peptide product from its own stability data, since no single standard shelf life applies [4]. Combined with FDA's aggregation and impurity concerns for unapproved peptides, that is why this page gives no formula, unit conversion or step-by-step measurement for reconstituting any product.